Patients With Stents Benefit From Clopidogrel

Patients With Stents Benefit From Clopidogrel

The FDA exclusivity for Plavix (clopidogrel) ended on May 17, 2012, while patent protection expires January 31, 2014. This exciting news brings Clopidogrel CAS# 113665-84-2, to the forefront of pharmaceutical news. With sales of Plavix generating billions of dollars for Bristol-Myers Squibb/Sanofi Pharmaceuticals, researchers are clamoring to create generic options of clopidogrel. As an antiplatelet drug that works by keeping the platelets in your blood from clotting, clopidogrel if effectual in preventing heart attacks and strokes in predisposed patients. Offered in doses of both 75 and 300 milligrams, clopidogrel is typically dosed as one 75 milligram tablet per day, with or without food. For adults with Atrial Fibrillation or those adults who cannot take oral anticoagulants, such as warfarin, they may also be prescribed 75 milligrams once daily. In patients with unstable angina, or those who have recently had a heart attack, they may be prescribed a one time dose of 300 milligrams, followed by a 75 milligrams once daily treatment.


On June 5th, 2012 findings were reported from the Veterans Administration Drug-Eluting Stent Study. The publication,  Circulation: Cardiovascular Interventions revealed positive results from this study, indicating an effectual outcome for patients who received clopidogrel after bare-metal and drug-eluting stent placements. This study involved 29,175 veterans, and took place between 2002 and 2006. The risks for those patients who received prolonged clopidogrel, for greater then one year, was associated with a lower adjusted risk of death for both drug-eluting and bare metal stents. The greatest effects were for the patients who were treated with drug-eluting stents and who received prolonged clopidogrel, as they had a significantly lower rate of either death or myocardial infarction. According to William Fay, director of the division of cardiovascular medicine for the University of Missouri and, more than 500,000 heart stents are placed each year in the U.S.  This estimate is only expected to grow with the elderly population growing and the advancement of medical care and technology. Clopidogrel has been a gold standard medication for stent patients and will continue to be.

Patients who take Plavix should inform their doctor if they have any bleeding disorders, such as bleeding ulcers or hemophilia. Side effects may include exhaustion, dizziness, headache, nausea, stomach pain, diarrhea, itching and an increased risk of nosebleeds.

Clopidogrel Bisulfate is also available from LGM Pharma, as well as the Clopidogrel Bisulfate TEVA API (TAPI) for compounding purposes.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.




  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service